-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target

Benzinga·06/15/2026 14:03:03
Listen to the news
Citizens analyst Reni J. Benjamin reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Market Outperform and maintains $34 price target.